Trending...
- Affordable Braces in Allentown Made Accessible Through Exeter Smiles' Flexible Payment Options
- New Metallized PE Film from Pregis Brings Recyclability to High-Barrier Food Packaging at Pack Expo International in Chicago
- PropAccount.com Launches Marketing Hub Within PropGenie, Giving Prop Firm Operators an Automated Marketing Team
EXTON, Pa., Sept. 24, 2020 /PRNewswire/ -- The 2020 audit included in Spherix's RealWorld Dynamix™: Biologic/Small Molecule Switching in IBD (US) service focuses on a critical facet of overall biologic and JAK therapy prescribing for ulcerative colitis (UC) and Crohn's disease (CD) patients – advanced therapy switching. The study captures the myriad of data surrounding the process by which inflammatory bowel disease (IBD) patients are switched from one advanced therapy to another and corroborates Spherix's physician-reported data on the downward trend of branded TNF inhibitor use (namely AbbVie's Humira and Janssen's Remicade) due to the continued uptake of alternate mechanism of action (AMOA) agents, such as Takeda's Entyvio and Janssen's own Stelara.
In both UC and CD, Humira and infliximab (Remicade and its biosimilars) still hold the largest patient share in the first-line setting. It is only in examining the switch dynamic, does the opportunity for AMOAs become fully evident. In UC, the patient records indicate that Humira's share by line of therapy is reduced by two-thirds in the progression from the first- to third-line setting, while infliximab's share is reduced by one-half from just first to second line. In contrast, Entyvio share in UC triples in the progression from first line to second line, while Stelara's share increases three-fold from just second to third line. Pfizer's Xeljanz experiences an almost five-fold increase in UC share in the progression from first-line to third-line UC therapy. Similar patterns were found when examining the change in share by line of therapy for the TNFs and AMOAs indicated in CD.
In measuring the reasons for needing to switch IBD patients in the first place, the audited records identify that efficacy, in different forms, is the primary driver of the current switch patterns. Primary efficacy failure, secondary efficacy failure, and lack of full clinical remission are the top three factors selected by physicians, regardless of the therapy they are switching from in both UC and CD. This indicates that failure in primary clinical endpoints, secondary clinical endpoints, and patient remission all play a role in the decision to switch an IBD patient from one biologic/JAK therapy to another. However, Entyvio and Stelara both provide evidence that they can address those efficacy needs with the VARSITY study results in UC from last year and with more recent clinical data for Stelara among TNF refractory patients in CD.
More on The PennZone
First for Entyvio, the favorable efficacy perceptions relative to Humira from the VARSITY study resulted in the therapy being selected most often in UC switches to address the "primary efficacy failure" of the original first-line therapy. Entyvio also had the most common selection in terms of addressing the lack of "full clinical remission" with the original first-line therapy. Likewise, Stelara's recent, favorable data released relative to Entyvio in TNF-refractory CD patients led to the IL-12/23 inhibitor being the most common selection in terms of addressing the primary efficacy failure of the original first-line therapy. Further evidence of Stelara's perceived advantages in CD is apparent, as the brand captured the highest percentage of mild, severe, and active flare CD patients at their most recent switch.
Physicians who started IBD patients on first-line TNF therapy were not the only prescribers open to a different mechanism of action when needed. The audit results also indicate that, in the less common situation when AMOAs, such as Entyvio and Stelara, are prescribed first-line in UC and CD, a TNF therapy is much more likely to be prescribed next if that AMOA therapy fails. Anecdotally, the study also captured high gastroenterologist agreement with the statement "after a first-line primary TNF-failure in IBD, I usually move to a biologic with a different MOA." Thus, the overall switch to AMOAs in second-line in IBD is part of an even broader continual search for optimal efficacy when a mechanism of action cannot address that need as a first-line or even second-line therapy.
While Entyvio and Stelara are leading the switch-to AMOAs in IBD, switching patterns for the JAK-1 inhibitor, Xeljanz, are also intriguing. Xeljanz UC prescribing was highest in the third-line setting. Audit records indicate that Xeljanz is second among current UC therapies (behind Entyvio) in the percentage of patients who are switched due to primary and secondary efficacy failure in the prior therapy and second (behind Stelara) in patients with active flares. Furthermore, Pfizer's JAK has the lowest percentage of IBD patients with concomitant treatment from conventional therapies. Collectively, these data and the overall prescribing patterns for Xeljanz likely reflects physician trial of different mechanisms as patients are unable to obtain the necessary level of efficacy from the prior two lines of therapy. Unfortunately, this pattern of prescribing also led to Xeljanz having the highest percentage of UC patients switching away from it due to its "efficacy profile."
More on The PennZone
Therapies in development may rely heavily on IBD patient switching when they are eventually launched on the IBD market. The pipeline agent most able to capitalize on that potential opportunity is Entyvio SC. When asked which pipeline agent they would have used in place of their current UC and CD therapies, gastroenterologists selected Entyvio SC, more than any of the other listed therapies in development, as a replacement for Entyvio, Humira, Remicade, Stelara, and Xeljanz. While respondents anticipate Entyvio SC to cannibalize the IV formulation of Entyvio, other therapies could also be "at risk" if Entyvio SC is approved and launched.
When asked whether Entyvio SC would have been prescribed instead of the current switch-to UC therapy, 78% of the current Entyvio IV records indicated "yes," while around half of the Humira and Stelara records were also in the affirmative. Likewise, when asked whether Entyvio SC would have been prescribed instead of the actual CD therapy, 70% of the current Entyvio IV records indicated "yes", while around half of the Humira records were also positive. Ozanimod, an oral sphingosine-1-phosphate receptor (S1P) being developed by BMS, is another "therapy to watch" in IBD as it received the second highest candidate scores for both UC and CD, behind Entyvio SC.
About RealWorld Dynamix™
RealWorld Dynamix™: Biologic/Small Molecule Switching in IBD (US) is an independent, data-driven service unmasking real patient management patterns through annual reports based on chart audits of ~1,000 patients. The report uncovers the "why" behind treatment decisions, includes year over year trending to quantify key aspects of market evolution, and integrates specialists' attitudinal & demographic data to highlight differences between stated and actual treatment patterns.
About Spherix Global Insights
Spherix Global Insights is a hyper-focused market intelligence firm that leverages our own independent data and expertise to provide strategic guidance, so biopharma stakeholders make decisions with confidence. We specialize in select immunology, nephrology, and neurology markets.
All company, brand or product names in this document are trademarks of their respective holders.
For more information contact:
Kristen Henn, Business Development Manager
Email: [email protected]
www.spherixglobalinsights.com
SOURCE Spherix Global Insights
Related Links
http://www.spherixglobalinsights.com
In both UC and CD, Humira and infliximab (Remicade and its biosimilars) still hold the largest patient share in the first-line setting. It is only in examining the switch dynamic, does the opportunity for AMOAs become fully evident. In UC, the patient records indicate that Humira's share by line of therapy is reduced by two-thirds in the progression from the first- to third-line setting, while infliximab's share is reduced by one-half from just first to second line. In contrast, Entyvio share in UC triples in the progression from first line to second line, while Stelara's share increases three-fold from just second to third line. Pfizer's Xeljanz experiences an almost five-fold increase in UC share in the progression from first-line to third-line UC therapy. Similar patterns were found when examining the change in share by line of therapy for the TNFs and AMOAs indicated in CD.
In measuring the reasons for needing to switch IBD patients in the first place, the audited records identify that efficacy, in different forms, is the primary driver of the current switch patterns. Primary efficacy failure, secondary efficacy failure, and lack of full clinical remission are the top three factors selected by physicians, regardless of the therapy they are switching from in both UC and CD. This indicates that failure in primary clinical endpoints, secondary clinical endpoints, and patient remission all play a role in the decision to switch an IBD patient from one biologic/JAK therapy to another. However, Entyvio and Stelara both provide evidence that they can address those efficacy needs with the VARSITY study results in UC from last year and with more recent clinical data for Stelara among TNF refractory patients in CD.
More on The PennZone
- 3ptechies Makes Its Articles Audio-Ready With Instaread Voice Technology
- Genuine Hospitality, LLC Selected to Operate Fairfield Inn & Suites Tampa Wesley Chapel
- Pregis to Highlight EPR Expertise, Sustainable Packaging Solutions and Live Automation Demonstrations at Pack Expo International 2026
- Infinity Infusion Solutions Launches "Women Leading Infusion Care" Campaign for National Women in Business Month
- HuskyTail Digital Puts AI to Work Behind the Scenes to Cut Client Turnaround Time
First for Entyvio, the favorable efficacy perceptions relative to Humira from the VARSITY study resulted in the therapy being selected most often in UC switches to address the "primary efficacy failure" of the original first-line therapy. Entyvio also had the most common selection in terms of addressing the lack of "full clinical remission" with the original first-line therapy. Likewise, Stelara's recent, favorable data released relative to Entyvio in TNF-refractory CD patients led to the IL-12/23 inhibitor being the most common selection in terms of addressing the primary efficacy failure of the original first-line therapy. Further evidence of Stelara's perceived advantages in CD is apparent, as the brand captured the highest percentage of mild, severe, and active flare CD patients at their most recent switch.
Physicians who started IBD patients on first-line TNF therapy were not the only prescribers open to a different mechanism of action when needed. The audit results also indicate that, in the less common situation when AMOAs, such as Entyvio and Stelara, are prescribed first-line in UC and CD, a TNF therapy is much more likely to be prescribed next if that AMOA therapy fails. Anecdotally, the study also captured high gastroenterologist agreement with the statement "after a first-line primary TNF-failure in IBD, I usually move to a biologic with a different MOA." Thus, the overall switch to AMOAs in second-line in IBD is part of an even broader continual search for optimal efficacy when a mechanism of action cannot address that need as a first-line or even second-line therapy.
While Entyvio and Stelara are leading the switch-to AMOAs in IBD, switching patterns for the JAK-1 inhibitor, Xeljanz, are also intriguing. Xeljanz UC prescribing was highest in the third-line setting. Audit records indicate that Xeljanz is second among current UC therapies (behind Entyvio) in the percentage of patients who are switched due to primary and secondary efficacy failure in the prior therapy and second (behind Stelara) in patients with active flares. Furthermore, Pfizer's JAK has the lowest percentage of IBD patients with concomitant treatment from conventional therapies. Collectively, these data and the overall prescribing patterns for Xeljanz likely reflects physician trial of different mechanisms as patients are unable to obtain the necessary level of efficacy from the prior two lines of therapy. Unfortunately, this pattern of prescribing also led to Xeljanz having the highest percentage of UC patients switching away from it due to its "efficacy profile."
More on The PennZone
- AI, Real-World Data "RWD" and U.S. Expansion Put Predictive Healthcare in Focus for POMDOCTOR Ltd. (N A S D A Q: POM)
- $11.18 Million DARPA Award Ignites a Major New Catalyst as FDA, Robotic TMS and Commercialization Milestones Converge for NRx Pharmaceuticals, Inc
- Dave's Auto Services Launches Free Seven-Week Fall Maintenance Series for Boyertown-Area Drivers
- P-Wave Classics to publish Thomas Holcroft's The Adventures of Hugh Trevor in three volumes, beginning 19 January
- Ad Leverage Sponsors ServiceTitan Pantheon 2026, Supporting Education and Growth in the Home Services Industry
Therapies in development may rely heavily on IBD patient switching when they are eventually launched on the IBD market. The pipeline agent most able to capitalize on that potential opportunity is Entyvio SC. When asked which pipeline agent they would have used in place of their current UC and CD therapies, gastroenterologists selected Entyvio SC, more than any of the other listed therapies in development, as a replacement for Entyvio, Humira, Remicade, Stelara, and Xeljanz. While respondents anticipate Entyvio SC to cannibalize the IV formulation of Entyvio, other therapies could also be "at risk" if Entyvio SC is approved and launched.
When asked whether Entyvio SC would have been prescribed instead of the current switch-to UC therapy, 78% of the current Entyvio IV records indicated "yes," while around half of the Humira and Stelara records were also in the affirmative. Likewise, when asked whether Entyvio SC would have been prescribed instead of the actual CD therapy, 70% of the current Entyvio IV records indicated "yes", while around half of the Humira records were also positive. Ozanimod, an oral sphingosine-1-phosphate receptor (S1P) being developed by BMS, is another "therapy to watch" in IBD as it received the second highest candidate scores for both UC and CD, behind Entyvio SC.
About RealWorld Dynamix™
RealWorld Dynamix™: Biologic/Small Molecule Switching in IBD (US) is an independent, data-driven service unmasking real patient management patterns through annual reports based on chart audits of ~1,000 patients. The report uncovers the "why" behind treatment decisions, includes year over year trending to quantify key aspects of market evolution, and integrates specialists' attitudinal & demographic data to highlight differences between stated and actual treatment patterns.
About Spherix Global Insights
Spherix Global Insights is a hyper-focused market intelligence firm that leverages our own independent data and expertise to provide strategic guidance, so biopharma stakeholders make decisions with confidence. We specialize in select immunology, nephrology, and neurology markets.
All company, brand or product names in this document are trademarks of their respective holders.
For more information contact:
Kristen Henn, Business Development Manager
Email: [email protected]
www.spherixglobalinsights.com
SOURCE Spherix Global Insights
Related Links
http://www.spherixglobalinsights.com
0 Comments
Latest on The PennZone
- Virtually Tour Heritage at South Brunswick's Resort-Style Living - Experience Indoor and Outdoor Amenities at Your Fingertips
- Derek Cook's Roofing Encourages Homeowners to Prepare for Fall Weather
- Boston Industrial Solutions Expands Product Offering with Pad Printing Pads and Silicone for Custom Pad Manufacturing
- Rodeo FX Originals Appoints Yvann Thibaudeau Head of Development & IP
- Phoenix 5/7 Emerges as a Genre-Fluid Artist Collective
- Massage Revolution Expands to Santa Monica With New Wilshire Boulevard Location
- "Warrior Defined" Event Brings Men Together in Charlotte, With Calls for Events Across the U.S
- Dion Abadi Publishes Free Collector Tips Hub for Art and Jewelry Buyers
- World-Renowned Body Language Expert Mark Bowden Headlines INSPIRE Northwest 2026 in Wenatchee, WA
- ASN Software Introduces New California CARS Act Dealer Updates
- USA Air Management Marks 30 Years of Air Duct Cleaning in NJ Urges Homeowners to Schedule Dryer Vent Cleaning Before Heating Season
- Dr. Jay Johannigman Returns to Cincinnati Following 46 Years of Military Service
- Mud Morganfield Bares His Soul on 7" Single, 'Deep Gospel'
- Allstream Energy Partners, SEO Experts in Oil and Gas, Awarded Gas Processing OEM Agreement
- Growth Story Expands: $54.6M Contract, $30M Revenue Run Rate, 800+ Customers, 50+ Patents & New AI Cybersecurity Products for Cycurion, Inc $CYCU
- Sky Quarry Restarts Nevada's Only Crude Oil Refinery — A Major New Chapter Begins in This Highly Lucrative sector for N A S D A Q: SKYQ
- Nutriband Inc. (N A S D A Q: NTRB) Breaks Into Uncharted Territory: 52-Week High Eclipsed as Shares Surge 22% —AVERSA™ Puts Investors on High Alert
- Jacqui Condon Selected to Workers' Compensation Panels for Three Professional Athlete Associations
- New Metallized PE Film from Pregis Brings Recyclability to High-Barrier Food Packaging at Pack Expo International in Chicago
- Transformational $104 Million Musculoskeletal Healthcare Opportunity as Expansion Strategy Accelerates for Cardiff Lexington Corp (Stock Symbol: CDIX)